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Abstract: The current study examined and compared the willingness of young Black men 
who have sex with men (YBMSM) to accept pre-exposure prophylaxis (PrEP), adult male 
circumcision, and condoms for reducing their risk of HIV acquisition. The majority (67%) 
reported unprotected receptive anal sex in the last six months. About three-quarters (71%) 
would accept using PrEP if it was 100% effective. Cost influenced PrEP acceptance with 
19% indicating acceptance at $100 per month co-pay. Of those not circumcised, 50% 
indicated willingness if circumcision was 100% effective. Acceptance of circumcision 
decreased markedly to 17% with co-pays of $100. About 73% of men were willing to use 
condoms if they were 100% effective and 50% indicated a willingness at the cost of $10 
per month. The findings suggest that condom use promotion strategies should remain at the 
forefront of public health efforts to control HIV incidence among YBMSM. 
Keywords: African American men who have sex with men; HIV/AIDS; condoms; PrEP; 
circumcision 
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1. Introduction 
The southern region of the United States comprises the largest percentage (18%) of Black 
Americans and accounts for 46% of all new HIV diagnoses and more than 55% of HIV prevalence [1]. 
Young Black men who have sex with men (YBMSM) represent 73% of HIV incidence among all 
Black men and 37% of all MSM [2,3]. YBMSM aged 13–29 years are the only subgroup to have 
experienced a continuous increase in HIV incidence rates during the last three years [4]. Based on 
these marked racial/ethnic disparities, many questions remain about the acceptance of newly 
developed as well as established HIV prevention strategies for YBMSM. 
The use and effectiveness of condoms against HIV and other sexually transmitted infections (STI) 
are empirically supported, showing a 59% decrease in STI acquisition with accurate and consistent 
condom utilization [5–9]. Despite this effectiveness, continued disparities have increased the need for 
additional approaches to HIV prevention [10]. In recent years, biomedical strategies have reemerged as 
promising efforts in this regard.  
Pre-exposure prophylaxis (PrEP) is an empirically supported antiretroviral medication consumed 
prior to HIV exposure to prevent potential acquisition [11]. Results from the PrEP Initiative study 
showed a 44% reduction in HIV risk transmission among MSM and eventually led to the release of 
federal guidelines and FDA approval for PrEP as an HIV prevention strategy [12–14]. PrEP acceptability 
has varied between 30% and 80% [15–17] and its uptake has been influenced by demographic 
characteristics (e.g., age and education), sexual risk behavior and perception of risk [18,19].  
Another biomedical strategy is adult male circumcision [20,21], which has been recommended as 
part of a comprehensive approach to HIV prevention [22]. However, effectiveness data have varied 
among MSM [23–25] with a paucity of data specific to Black MSM [26,27].  
The continued increase of HIV in YBMSM has created a need to understand what prevention 
strategies are most acceptable to this population. Therefore, the purpose of this study was to describe 
the willingness of YBMSM to accept the use of condoms, PrEP, and circumcision for reducing their 
risk of HIV acquisition. 
2. Methods  
Participants were recruited between 15 January 2013 and 14 February 2013, through banner 
advertisements on the Black Gay Chat website. These advertisements were restricted to residents of 
Mississippi, Louisiana, Alabama and Georgia. Website visitors who clicked on a banner ad were 
redirected to the internet-survey for completion. The survey was developed through the Qualtrics 
online system and included no accessibility limitations (i.e., desktop or mobile preferences). Young 
men were eligible if they had sex with a man in the past six months, were 18–39 years of age, and 
identified as being African American or Black. Incentives were not provided. The survey was 
anonymous and assessed questions assessing demographics, sexual risk behavior and determinants in 
the utilization of HIV prevention methods. The Institutional Review Board at the University of 
Kentucky approved all study protocols. Data were analyzed using frequency distributions.  
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3. Results 
The sample consisted of young Black men who have sex with men (YBMSM) (N = 95), ages 18–39 
years (mean = 26.8, SD = 5.66). In the last six months, 72% reported insertive anal sex and 74% 
reported receptive anal sex. The majority (71%) reported engaging in at least one act of anal sex that 
was not condom-protected. During the last six months, 67% reported at least one instance of engaging 
in unprotected receptive anal sex and 56% reported engaging in one instance of unprotected insertive 
anal sex (See Table 1).  
Table 1. Characteristics of the Study Sample, African American Men, Aged 18–39 (N = 95). 
Variable Mean (SD) n (%) 
Age 26.8 (5.66)  
Anal insertive (top) sex 
Yes 
No  
 
 
 
 
68 (71.6) 
27 (28.4) 
Anal insertive (top) sex  
with a condom  
 
 
 
Yes 
No 
 
50 (86.2) 
8 (13.8) 
Anal insertive (top) sex  
without a condom 
Yes 
 
 
 
33 (55.9) 
No   26 (44.1) 
Anal receptive (bottom) sex 
Yes 
No 
 
70 (73.7) 
25 (26.3) 
Anal receptive (bottom) sex  
with a condom 
Yes 
No 
 
 
 
49 (79.0) 
13 (21.0) 
Anal receptive (bottom) sex  
without a condom 
Yes 
No 
 
 
 
42 (66.7) 
21 (33.3) 
Nearly three-quarters (71%) of the men were willing to accept PrEP if it was 100% effective. 
Willingness to accept this method decreased with a lower level of effectiveness: 75% effectiveness 
(43%) and 50% effectiveness (21%). Cost had an influence on men’s willingness to accept PrEP: 19% 
were willing to accept the medication with a personal cost of $100. Table 2 provides greater details.  
The majority (75%) of the participants were circumcised. Of those young men who were not 
circumcised (n = 24), 50% indicated a willingness to be circumcised if this procedure was 100% 
effective in avoiding HIV infection. Acceptance of circumcision as an HIV prevention strategy 
decreased markedly to 17% with a personal cost of $100. Table 3 provides more information regarding 
the decline in acceptance based on cost and effectiveness.  
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Table 2. Acceptance of pre-exposure prophylaxis (PrEP) as a Safe Sex Measure (N = 95). 
Variable n (%) 
PrEP acceptance based on 100% effectiveness against HIV  
Yes 67 (70.5) 
No 28 (29.5) 
PrEP acceptance based on 75% effectiveness against HIV  
Yes 41 (43.2) 
No 54 (56.8) 
PrEP acceptance based on 50% effectiveness against HIV  
Yes 20 (21.1) 
No 74 (77.9) 
PrEP acceptance based on cost-Free  
Yes 58 (61.1) 
No 36 (37.9) 
PrEP acceptance based on cost-$100 or less per month  
Yes 18 (18.9) 
No 77 (81.1) 
PrEP acceptance based on cost-$500 per month  
Yes 16 (16.8) 
No 77 (81.1) 
PrEP acceptance based on cost-$1000 per month  
Yes 13 (13.7) 
No 82 (86.3) 
Table 3. Acceptance of Circumcision as a Safe Sex Measure (N = 24). 
Variable n (%) 
Circumcised   
Yes 71 (74.7) 
No 24 (25.3) 
Circumcision acceptance based on 100% effectiveness against HIV  
Yes 12 (50.0) 
No 12 (50.0) 
Circumcision acceptance based on 75% effectiveness against HIV  
Yes 9 (37.5) 
No 15 (62.5) 
Circumcision acceptance based on 50% or less effectiveness 
against HIV 
 
Yes 8 (33.3) 
No 16 (66.7) 
Circumcision acceptance based on cost-Free  
Yes 13 (54.2) 
No 11 (45.8) 
Circumcision acceptance based on cost-$100 or less   
Yes 4 (16.7) 
No 20 (83.3) 
Circumcision acceptance based on cost-$500 or more   
Yes 1 (4.2) 
No 23 (95.8) 
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The majority of the men (73%) were willing to use condoms if they were 100% effective, with 50% 
indicating this willingness to accept this prevention strategy at a cost of $10 per month. Table 4 
provides greater detail about these findings.  
Table 4. Acceptance of condoms as a safe sex measure (N = 95). 
Variable n (%) 
Condom acceptance based on 100% effectiveness against HIV  
Yes 69 (72.6) 
No 26 (27.4) 
Condom acceptance based on 75% effectiveness against HIV  
Yes 57 (60.0) 
No 38 (40.0) 
Condom acceptance based on 50% or less effectiveness against HIV  
Yes 40 (42.1) 
No 55 (57.9) 
Condom/Lubricant acceptance based on cost-Free  
Yes 64 (67.4) 
No 31 (32.6) 
Condom/Lubricant acceptance based on cost-$10 per month  
Yes 47 (49.5) 
No 48 (50.5) 
Condom/Lubricant acceptance based on cost-$100 per month  
Yes 18 (18.9) 
No 77 (81.1) 
4. Discussion 
Regardless of the HIV prevention method being offered, small personal costs have a substantial 
adverse influence on acceptance of PrEP, circumcision or condom use. Generally, the level of 
acceptance for all three methods was low, unless the method was rated at 100% efficacy and provided 
at minimal cost to the participant. The findings suggest that even under ideal circumstances (100% 
effective and free) a large proportion of men may not be willing to use any of these methods. This 
observation led to a post-hoc analysis that calculated the percent of men who would not accept the 
method even under both ideal circumstances (100% efficacy and free). This analysis was achieved 
through the use of a contingency table. These findings showed that 27% would not accept PrEP, 42% 
of those not circumcised would refuse do so, and 21% would not use condoms. These values are high 
given that the ideal circumstances are unlikely to exist, with the possible exception of condom use. 
Findings regarding PrEP are particular intriguing. The current findings are similar to those from 
other studies that examined barriers to PrEP acceptance [18]. Previous studies have shown that 
government funding to assist in the accessibility of PrEP could be a facilitator to the acceptance of this 
HIV prevention method [18]. Cost-effectiveness has been one of the primary considerations in the use 
of public funds for these prevention strategies. Delivery of PrEP was found to be a cost-effective 
strategy for high-risk populations [28,29], but acceptance among YBMSM may alter this equation. 
Resources to assist in subsidizing personal costs to YBMSM may be needed to enhance uptake of 
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these prevention strategies [30]. PrEP effectiveness has been established from clinical trials when 
combined with condom use, HIV testing and other established prevention methods [15,30,31]. Although 
the current evidence supports this strategy, further research is needed regarding whether YBMSM most 
at-risk of HIV will indeed seek out a provider to give them PrEP at a price they can afford. 
5. Limitations 
These findings are limited based on the validity of self-reported data. The participants were a 
sample of men who opted into an online banner-ad survey and therefore the findings are subject to 
selection bias. Convenience sampling and restrictions to the southern region of the U.S. limits the 
generalizability of the findings to other populations of MSM. The results are based on a small sample 
size and therefore further research is warranted. Additionally, the findings provide limited insight to 
the participants’ knowledge of HIV prevention methods. This information could be a facilitator or barrier 
to their decision to prefer certain safe sex methods and should be further examined in future research. 
6. Conclusions 
Biomedical approaches to HIV prevention, such as the use of PrEP and circumcision, will 
ultimately require patient acceptance. Availability alone may not be an adequate response. Given 
optimal circumstances (i.e., 100% effective and no personal costs) PrEP and circumcision are less 
acceptable to YBMSM than condom use. Because these optimal circumstances may never exist, 
findings suggest that condom use promotion strategies should remain at the forefront of public health 
efforts to control HIV incidence among YBMSM. Further, the study findings suggest that HIV 
preventive measures offered to YBMSM may not be widely embraced, including condom use. Apathy 
about preventing HIV infection may be a barrier working against efforts to innovatively protect this 
population. Thus, the role of behavioral science in HIV prevention is one that can complement and 
enhance emergent biomedical strategies.  
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